Recently, the adenovirus expression vector attracts much attention for the application to gene therapy and the method to purify and concentrate adenovirus without loss of infectivity has become very important, especially for animal experiments and gene therapy of humans.
INTRODUCTION
The application of replication-deficient recombinant adenoviruses began in the field of experimental gene therapy of human diseases, such as cystic fibrosis (1, 2) . Because this vector can accept a large size of foreign gene (up to 7.5 kb) and can infect either non-dividing or resting cells, a wide variety of applications can be expected in various fields such as in central nervous system (3), muscle (4) and liver (5) tissues. Moreover, this vector is a possible candidate for the live vaccine (6) ; thus, a method to purify and concentrate recombinant adenoviruses becomes important.
Although the retrovirus vector has been used for ex vivo gene therapy, it is known to be rather difficult to concentrate this vector without loss of infectivity (7).
We have recently developed an efficient method to construct recombinant adenoviruses (S. Miyake et al., in preparation). Consequently, it is now expected that many researchers will soon need in vivo experiments, that is, inoculation of the recombinant adenoviruses into animals. Before the inoculation, the recombinant virus should be purified and concentrated. However, the established methods (8, 9) to purify adenovirus virions in a buoyant CsCI density-gradient often cause a loss of the infectivity. The present report describes a simple and efficient method to purify adenovirus without loss of the infectivity with CsCI step gradients, a modified step gradient method to purify bacteriophage lambda (10 
RESULTS

Procedure for Purifying Adenovirus
A simple method to purify and concentrate infectious recombinant adenovirus was established and summarized in Fig 
Stability of Purified Virus
To determine stability of the purified virus, each sample of the purified virus stocks after dialysis was subjected to either one cycle of freezing-and-thawing or two cycles of 30-sec sonication (Fig. 2) . More than 40% of the infectivity of that of the stock before purification was maintained after the freezing-and-thawing, when either HEPES-EDTA buffer or PBS (-) buffer was used. When the HEPES-MgCl2 buffer was used, however, the titer reduced to 19% of the original infectivity. Similarly, while virus titers after the sonication in HEPES-EDTA buffer or PBS (-) buffer retained at least 20% of the infectivity; the titer dropped to 7.5% in HEPES-MgCl2 buffer. The results suggest that the contents of the stock solution are important for maintaining the infectivity after sonication and freezing-and-thawing and that the purified virus is more stable in HEPES-EDTA buffer or in PBS (-) buffer than in HEPES-MgCl2 buffer. The total infectivity of the viral stock before purification was regarded as 100% (see Table I , footnote 2).
DISCUSSION
The titer of the conventional adenovirus stock often reaches 109 PFU/ml and therefore is usually enough for in vitro experiments without further concentration. Of course, however, the expression of the desired gene essentially increases 10-fold when a 10-fold concentrated virus stock is used. To apply recombinant adenoviruses to in vivo experiments, the steps of purification and concentration are absolutely necessary because: (i) the volume of the inoculum is often limited , (ii)
it is difficult to distinguish whether the observed effect is due to the desired in vivo-expressed protein or due to the carry-over of the protein produced during vi- The method described here is based essentially on the purification procedure of bacteriophage lambda. Essential modification of the conditions was the density of two cycles of CsCl step gradients from 3M/5M for lambda phage to 2.2M/4M for adenovirus, in response to their particle density. The method with a step gradient described in this report appeared to have several advantages over with the previous method that uses buoyant gradient.
(i) This method is easier and quicker. Although the previous method needs two or three days for the whole procedure, this method takes only one day; the quick procedure may eventually reduce loss of infectivity.
(ii) The step gradient possibly prevents overconcentrating virions which may cause aggregation and loss of infectivity.
(iii) The virus purity after two cycles of step gradients may be higher than that after two cycles of buoyant gradients, because separation of the target molecule was maximized by optimizing the CsCl densities of the steps. Efficient elimination of human cellular proteins is important for quality control for gene therapy. We examined also the effects of dialysis buffers on the stability of the purified virus, because purified and concentrated adenovirus often loses its infectivity by self-aggregation during dialysis and storage at -80 C. Another important reason is that the purified virus stock is often used for inoculation to animals and hence PBS is usually preferred for this purpose. We showed that the virus infectivity was maintained in all three buffers containing 10% glycerol. Glycerol was added mainly to stabilize the virus during storage at -80 C and could be omitted if used immediately after dialysis. HEPES buffer is used because of its stronger buffer action and safety for animal cells than Tris . buffer. We recommend HEPES-EDTA-glycerol buffer as well as the PBS-glycerol buffer. Rosenfeld et al.
(1) used Tris-MgCl2-glycerol buffer similar to our HEPES-MgCl2-glycerol buffer, but this buffer showed only limited stability after either freeze-thaw or sonication: therefore, we do not recommend this buffer system. 
